Market Place
Sourcing Support
Onconetix`s Proteomedix Licenses Ip To Immunovia
22 Sep 2025 //
GLOBENEWSWIRE
Immunovia`s Clariti Study Selected For Leading GI Conference
03 Mar 2025 //
PR NEWSWIRE
Immunovia Study Published in Leading Protein Research Journal
20 Dec 2024 //
PR NEWSWIRE
End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding
19 Dec 2024 //
PR NEWSWIRE
Immunovia CEO and Board to Fully Exercise TO2 Warrants
18 Dec 2024 //
PR NEWSWIRE
Immunovia to Host Webcast on Pancreatic Cancer Test Validation
16 Dec 2024 //
PR NEWSWIRE
Immunovia announces financial calendar for financial year 2025/2026
11 Dec 2024 //
PR NEWSWIRE
Immunovia to present at the Redeye Technology & Life Science Day
28 Nov 2024 //
PR NEWSWIRE
Immunovia Presents Data from PRECEDE Pancreatic Cancer Consortium
07 Nov 2024 //
PR NEWSWIRE
Immunovia Presents Pancreatic Cancer Study At AACR Conference
16 Sep 2024 //
PR NEWSWIRE
Immunovia`s Test Included In NIH-Funded Pancreatic Cyst Study
05 Aug 2024 //
PR NEWSWIRE
Immunovia Publishes Interim Report for January-June 2024
05 Aug 2024 //
PR NEWSWIRE
Immunovia AB Annual Meeting Held On 19 June 2024
19 Jun 2024 //
PR NEWSWIRE
Immunovia Announces SEK 70M Rights Issue, Bridge Loans
20 May 2024 //
PR NEWSWIRE
Immunovia publishes the annual report for 2023
29 Apr 2024 //
PR NEWSWIRE
Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director
29 Apr 2024 //
PR NEWSWIRE
Invitation to Immunovia`s Q1 presentation
23 Apr 2024 //
PR NEWSWIRE
Immunovia’s model-development study of next-generation pancreatic cancer
23 Apr 2024 //
PHARMABIZ
Immunovia Updates Financial Calendar
22 Apr 2024 //
PR NEWSWIRE
Invitation to Immunovia`s Q3 presentation
02 Nov 2023 //
PR NEWSWIRE
Immunovia to Restructure to Focus Resources on its Next-Generation Blood Test
12 Jul 2023 //
PR NEWSWIRE
Chief Executive Officer, Jeff Borcherding, buys Immunovia shares
09 Jun 2023 //
PR NEWSWIRE
Immunovia Publishes Interim Report for January-March 2023
23 May 2023 //
PR NEWSWIRE
Immunovia to discuss adoption of IMMray™ PanCan-d with key opinion leaders
26 Apr 2023 //
PR NEWSWIRE
Immunovia publishes the annual report for 2022
21 Apr 2023 //
PR NEWSWIRE
Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers
19 Apr 2023 //
PR NEWSWIRE
Immunovia resolves on a rights issue of approximately SEK 202.2 million
20 Feb 2023 //
PR NEWSWIRE
Immunovia realigning Swedish operations with strategic priorities
19 Jan 2023 //
PR NEWSWIRE
Immunovia Appoints Lara E. Sucheston-Campbell as Head of Medical Affairs
17 Jan 2023 //
PR NEWSWIRE
Centers for Medicare & Medicaid Services finalizes its payment determination
30 Nov 2022 //
PRNEWSWIRE
Immunovia launches a strategic partnership with Proteomedix
17 Oct 2022 //
PRNEWSWIRE
Immunovia reports positive update on physician experience programme
13 Oct 2022 //
PHARMABIZ
Immunovia market access increases when achieving Clinical Laboratory Permits
23 May 2022 //
PRNEWSWIRE
Communiqué from the Annual General Meeting in Immunovia AB
07 Apr 2022 //
PRNEWSWIRE
Immunovia Receives Accreditation from College of American Pathologists
08 Mar 2022 //
PRNEWSWIRE
IMMray PanCan-d - peer-reviewed, blinded validation study published
17 Feb 2022 //
PRNEWSWIRE
Immunovia, JW BioScience signs licensing deal for pancreatic cancer biomarkers
13 Sep 2021 //
BIOSPACE
Immunovia publishes data sets on the Optimization Study
26 Feb 2021 //
PRNEWSWIRE
